What Are the Stages of Non-Melanoma Skin Cancer?

 

Staging of a cancer provides a way to describe a tumor and whether and how far it has spread. The higher the stage number, the more widespread is the cancer. These stages are used to determine the type of treatment for non-melanoma skin cancer.

A staging system has been developed for basal and squamous cell carcinomas, the most common types of skin cancer. There is also a staging system for Merkel cell carcinoma. The rarity of other types of non-melanoma skin cancer makes it difficult to devise a staging system for these cancers.

The TNM System

Once a biopsy has been performed, a tool called the TNM (tumor, node, metastasis) system can be used to determine the stage of non-melanoma. This system is not a staging system in itself; rather, it is used to define the characteristics of the tumor so that the stage can then be determined.

The TNM system uses three criteria. The first is the size of the tumor itself (T). The second indicates the number of lymph nodes (N) involved. (The lymph system helps drain fluid and waste from the body, and lymph nodes are like tiny way stations that filter out impurities and help fight infection.) The third criterion is metastasis (M), or whether and how far the cancer has spread to other areas of the body. The results of these three criteria are combined to determine the stage of cancer.

In the TNM system for non-melanoma skin cancer, the “T” indicates the thickness of the tumor:

Tx: The primary, or original, tumor cannot be evaluated because of incomplete information.

 T0: There is no evidence of cancer in the tissue sample.

 Tis: Traces of cancer cells present on the skin lesion.

 T1: The tumor is 2 centimeters or smaller across its widest diameter.

 T2: The tumor is larger than 2 centimeters, but not larger than 5 centimeters across its widest diameter.

 T3: The tumor is larger than 5 centimeters across its widest diameter.

 T4: The tumor extends into tissue beneath the dermis (e.g., into cartilage, muscle, or bone).

The “N” in the TNM staging system indicates whether and how the regional lymph nodes have been affected by the cancer:

 Nx: The regional nodes cannot be assessed because of incomplete information.

 N0: There is no evidence of cancer in the regional lymph nodes.

 N1: Cancer cells have been found in one or more nodes.

The “M” in the TNM system refers to distant metastases—whether, and how far, the cancer has spread outside the original site:

 Mx: Distant metastases cannot be evaluated because of incomplete information.

 M0: There is no evidence that the cancer has spread beyond the original site.

 M1: The cancer has spread beyond the original site.

Staging of Basal and Squamous Cell Carcinomas

The stages of basal and squamous cell cancers are determined according to the TNM system:

American Joint Committee on Cancer (AJCC) Staging System for Basal and Squamous Cell Carcinomas
 StageTNMCharacteristics
Stage 0Tis
N0
M0
The cancer involves only the epidermis and has not spread to the dermis. Squamous cell carcinoma in situ is also called Bowen’s disease.
Stage IT1
N0
M0
The cancer is no larger than 2 centimeters (between three-quarters and  seven-eighths inch). It has not invaded into muscle, cartilage, or bone and has not spread to lymph nodes or other organs.
Stage IIT2      T3
N0 or N0
M0     M0
The cancer is larger than 2 centimeters and has not invaded into muscle, cartilage, or bone and has not spread to lymph nodes or other organs.
Stage IIIT4     AnyT
N0 or N1
M0     M0
The cancer has grown into tissues beneath the skin (such as muscle, bone, or cartilage) and/or it has spread to regional (nearby) lymph nodes. In this stage, the cancer has not spread to other organs such as the lungs or brain.
Stage IVAny T
Any N
M1
The cancer can be any size and may or may not have spread to local lymph nodes. It has spread to other organs, such as the lungs or brain.


Staging of Merkel Cell Carcinoma

  • Stage I - The cancer has not spread to lymph nodes or other parts of the body.
  • Stage II - The cancer has spread to nearby lymph nodes, but not to other parts of the body.
  • Stage III - The cancer has spread beyond the nearby lymph nodes and to other parts of the body.
  • Recurrent - The cancer has recurred after treatment, either in the same location or in another part of the body.

This content has been reviewed and approved by Myo Thant, MD.

This content was last modified on February 21, 2008 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health